Laura Viviani | Consultant
SciEthiQ

Since 2017, Laura has been working as consultant creating and leading global projects, many of them, dedicated to the implementation and regulatory acceptance of new non animal based assays in biologicals, including vaccines, and in general on supporting changes in the biomedical field. She collaborates with many international public health organizations, public and private institutions, and regulatory authorities globally. Before starting her consultancy activities, she managed global projects in Novartis, GSK and in the Developing Countries Vaccine Manufacturers Network (DCVMN). She received a degree in Philosophy of Science and she is a change management practitioner.

Appearances:

Day 2 (21st October) @ 11:00

Panel: Rethinking Livestock Vaccination for Emerging Threats

How will investments in pandemic-prevention vaccines affect the development of vaccines for emerging zoonotic threats in livestock?
How do regulatory systems for human and animal vaccines differ, and is it realistic to achieve similar approval speeds for both?
How can we balance rapid vaccine deployment with food safety, ecological, and trade risks, and do the benefits of live attenuated vaccines (e.g. for ASF) outweigh potential biosafety concerns?
How can economic incentives, such as advanced market commitments, best accelerate the development and market entry of new livestock vaccines?

Jeroen Kortekaas, Director, Viral Disease Research, Boehringer Ingelheim